Clinical trial Recruiting at 1 site Observational Ages 18 and up

Understanding neuromuscular connections in ALS patients

Official title: Reinnervation and Neuromuscular Transmission in Patients With Amyotrophic Lateral Sclerosis

Run by University of Aarhus · NCT06219759 · Data updated 2026-11-12

This study looks at how the connections between nerves and muscles change in people with ALS to see if there are differences compared to healthy individuals and those with other diseases.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment120 (estimated)
SponsorUniversity of Aarhus
Academic / other
Locations1 site (Aarhus, Central Jutland)
StatusRecruiting
StartedMay 17, 2024
Main results expectedDecember 2026
Study endsDecember 2026
Registry record updatedAugust 7, 2024
Trial IDNCT06219759 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include adults aged 18 and older who are suspected of having motor neuron disease or have been diagnosed with ALS within the last three months.

Probably not a fit

Patients with prior central or peripheral nervous system diseases, diabetes, or those who are pregnant may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to describe changes in neuromuscular connections in patients with amyotrophic lateral sclerosis (ALS). It consists of three substudies focusing on muscle reinnervation capacity, blood biomarkers related to neuromuscular transmission, and the relationship between nerve stimulation responses and physical fatigue. The study will include ALS patients, healthy controls, and disease controls to compare findings across different groups. Participants will undergo neurophysiological examinations to gather data on their condition.

Why it matters

Potential benefit: If successful, this study could lead to better understanding and management of ALS, potentially slowing disease progression.

How similar studies have gone: While similar studies have explored aspects of neuromuscular transmission in ALS, this specific approach focusing on reinnervation and biomarkers is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Referred to clinical neurophysiological examination on suspicion of motor neuron disease or diagnosed with ALS according to Gold Coast criteria within the last 3 months.
* Age ≥18 years old
* Able and willing to provide informed consent

Exclusion Criteria:

* Former central or peripheral nervous system disease
* Diabetes
* Electrophysiological signs of polyneuropathy at baseline visit
* Pacemaker
* Pregnancy

For disease controls the exclusion criteria are the same, but the inclusion criteria:

* Diagnosed with disease with slow, progressive loss of motor neurons
* Age ≥18 years old
* Able and willing to provide informed consent

Where it's running

  • Department of Neurology, Aarhus University Hospital
    Aarhus, Central Jutland, Denmark
    Recruiting

Study contacts

  • Principal investigator: Jesper H Storgaard, MD — Aarhus University and Department of Neurology, Aarhus University Hospital
  • Study coordinator: Jesper Storgaard, MD
  • Email: jesstg@rm.dk
  • Phone: 004520231903

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

  • Implanted Brain-Computer Interface to Help People with Severe Arm Impairment

    We’re testing the N1 System, a fully implanted brain interface in the motor cortex with a robot, to see if it can help adults with spinal cord injury, ALS, or chronic stroke use a computer or keyboard more easily.

    Recruiting Neuralink Corp · Miami, Florida · NCT07929792

  • Brain-computer interface chat tool for people with ALS

    This test compares a wearable brain-computer interface communication device to eye-tracking devices that people with ALS currently use to help them communicate.

    Recruiting Cognixion · Santa Barbara, California · NCT07871071

  • BIIB147 safety and how it behaves in adults with ALS

    This study tests BIIB147 in adults with ALS to see if it is safe and how the body handles it, including early and long-term effects.

    Recruiting at 2 sites Phase 1/2 Biogen · St Louis, Missouri and 1 other locations · NCT07855211

  • Aims to restore UNC13A function in people with ALS

    This trial tests TRCN-1023 in adults with ALS to see if it’s safe, tolerated, and shows early signs of benefit.

    Recruiting at 6 sites Phase 1/2 Trace Neuroscience, Inc. · Lübeck, Schleswig-Holstein and 5 other locations · NCT07674667

  • LTX-002 in adults with ALS

    A study will test whether the experimental drug LTX-002 is safe and tolerable in adults with ALS and see how the body handles the drug and how it affects ALS indicators.

    Recruiting at 4 sites Phase 1/2 Leal Therapeutics, Inc · Lübeck and 4 other locations · NCT07660614

  • Repeated ultrasound-assisted blood-brain barrier opening in ALS

    This trial tests whether repeatedly opening the blood-brain barrier with ultrasound is safe and may help people with ALS.

    Recruiting Phase 1/2 Assistance Publique - Hôpitaux de Paris · Paris · NCT07571486

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.